Tiziana Life Sciences
Manufacturing · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
14-15 Conduit Street, London, Greater Lo...Phone Number
+44 2074952379Website
www.tizianalifesciences.comRevenue
-Stock Symbol
TLSAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Tiziana Life Sciences
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory.Explore more
Tiziana Life Sciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tiziana Life Sciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Tiziana Life Sciences had a recent Job posting/layoffs
Product Launch: Get notified when Tiziana Life Sciences launches new products
Check if Tiziana Life Sciences has recently received funding, and reach out quickly before it becomes old news!
Tiziana Life Sciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Tiziana Life Sciences
Earning: See what the market has to say on Tiziana Life Sciences recently announced quarterly report
Check out if Tiziana Life Sciences is spiking on competitors!
Funding: Get notified immidiatlly once Tiziana Life Sciences has new funding data
Recommended Actions
Find VP level buyers at Tiziana Life Sciences
Find 3 more new buyers
Compare Similar Companies to Tiziana Life Sciences
Compare insights from companies similar to Tiziana Life Sciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tiziana Life Sciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tiziana Life Sciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tiziana Life Sciences.
Tiziana Life Sciences financials insights
Gather financial insights about Tiziana Life Sciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$10M
Share Placement
$57.3M
2024
Other Financing Round
$3.4M
2025
Stock/Share Issuance
$40K
Tiziana Life Sciences Tech Stack
A closer look at the technologies used by Tiziana Life Sciences
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Person-Based
Tiziana Life Sciences News & Media
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the signing of a Memorandum of Understanding (MOU) with the King Abdullah International Medical Research Center (KAIMRC) of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS),Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that a poster, titled “Phase 2a Trial of Intranasal Foralumab – BANYAN, a Healey ALS MyMatch Trial,” will be presented by Dr. Pinar Uysal today, Monday, August 24, 2026, from 4:30–6:30 p.m.Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 667,000 of the Company’s common shares on NASDAQ at $1.00 per share, bringing his total holdingTiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab
BOSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces quantitative PET imaging results from the third patient with Multiple System Atrophy (MSA) in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tiziana Life Sciences
Sign Up For FreeTo access detailed company insights
Tiziana Life Sciences Ltd. is a United Kingdom-based clinical-stage biotechnology company that is specialized in the developing transformative therapies for neurodegenerative and neuroinflammatory.... Read More
